TRANSLATIONAL GENOMICS RESEARCH INSTITUTE FOUNDATION: Form 990, tax year 2009

View the entire original 990 at ProPublica ↗

Organization
TRANSLATIONAL GENOMICS RESEARCH INSTITUTE FOUNDATION (EIN 33-1092191)
Tax period
2009-07-01 to 2010-06-30
Filed
2011-05-25
IRS object ID
201111459349300116
Schema version
2009v1.7
Source
Download XML · Original 990 at ProPublica

Every field in the e-filed return. Faint text is the IRS element name, for citing.

Return header ReturnHeader

FieldValueIRS element (for citing)
Timestamp2011-05-25T16:26:35-05:00Timestamp
Tax Period End Date2010-06-30TaxPeriodEndDate

Preparer Firm PreparerFirm

Preparer Firm Business Name PreparerFirmBusinessName

FieldValueIRS element (for citing)
Business Name Line1ERNST & YOUNG US LLPBusinessNameLine1

Preparer Firm US Address PreparerFirmUSAddress

FieldValueIRS element (for citing)
Address Line1TWO NORTH CENTRAL AVENUE STE 2300AddressLine1
CityPHOENIXCity
StateAZState
ZIP Code85004ZIPCode
FieldValueIRS element (for citing)
Return Type990ReturnType
Tax Period Begin Date2009-07-01TaxPeriodBeginDate

Filer Filer

FieldValueIRS element (for citing)
EIN331092191EIN

Name Name

FieldValueIRS element (for citing)
Business Name Line1THE TRANSLATIONAL GENOMICS RESEARCH INST FDNBusinessNameLine1
FieldValueIRS element (for citing)
Name ControlTRANNameControl
Phone6023438423Phone

US Address USAddress

FieldValueIRS element (for citing)
Address Line1400 E VAN BUREN SUITE 850AddressLine1
CityPHOENIXCity
StateAZState
ZIP Code85004ZIPCode

Officer Officer

FieldValueIRS element (for citing)
NameMICHAEL BASSOFFName
TitlePRESIDENTTitle
Date Signed2011-05-16DateSigned

Preparer Preparer

FieldValueIRS element (for citing)
Phone6023223000Phone
FieldValueIRS element (for citing)
Tax Year2009TaxYear
Build TS2016-02-24 21:20:13ZBuildTS

Form 990 IRS990

FieldValueIRS element (for citing)
Name Of Principal Officer PersonMICHAEL BASSOFFNameOfPrincipalOfficerPerson

Address Principal Officer US AddressPrincipalOfficerUS

FieldValueIRS element (for citing)
Address Line1400 E VAN BUREN SUITE 850AddressLine1
CityPHOENIXCity
StateAZState
ZIP Code85004ZIPCode
FieldValueIRS element (for citing)
Gross Receipts8955393GrossReceipts
Group Return For AffiliatesfalseGroupReturnForAffiliates
Organization501cXOrganization501c
Web SiteWWW.HELPTGEN.ORGWebSite
Type Of Organization CorporationXTypeOfOrganizationCorporation
Year Formation2004YearFormation
State Legal DomicileAZStateLegalDomicile
Activity Or Mission DescriptionBIOGENOMIC MEDICAL RESEARCH FUNDRAISING FOR THE TRANSLATIONAL GENOMICS RESEARCH INSITUTE (TGEN)ActivityOrMissionDescription
Nbr Voting Members Governing Body19NbrVotingMembersGoverningBody
Nbr Independent Voting Members16NbrIndependentVotingMembers
Total Nbr Employees0TotalNbrEmployees
Total Nbr Volunteers63TotalNbrVolunteers
Total Gross UBI0TotalGrossUBI
Net Unrelated Business Txbl Income0NetUnrelatedBusinessTxblIncome
Contributions Grants Prior Year4359865ContributionsGrantsPriorYear
Contributions Grants Current Year8918909ContributionsGrantsCurrentYear
Program Service Revenue Prior Year0ProgramServiceRevenuePriorYear
Program Service Revenue CY0ProgramServiceRevenueCY
Investment Income Prior Year49477InvestmentIncomePriorYear
Investment Income Current Year36484InvestmentIncomeCurrentYear
Other Revenue Prior Year0OtherRevenuePriorYear
Other Revenue Current Year0OtherRevenueCurrentYear
Total Revenue Prior Year4409342TotalRevenuePriorYear
Total Revenue Current Year8955393TotalRevenueCurrentYear
Grants And Similar Amnts Prior Year4545907GrantsAndSimilarAmntsPriorYear
Grants And Similar Amnts CY4259390GrantsAndSimilarAmntsCY
Benefits Paid To Members Prior Year0BenefitsPaidToMembersPriorYear
Benefits Paid To Members CY0BenefitsPaidToMembersCY
Salaries Etc Prior Year1077559SalariesEtcPriorYear
Salaries Etc Current Year1094471SalariesEtcCurrentYear
Total Prof Fundrsng Exp Prior Year0TotalProfFundrsngExpPriorYear
Total Prof Fundrsng Exp CY0TotalProfFundrsngExpCY
Total Fundrsng Exp Current Year1298565TotalFundrsngExpCurrentYear
Other Expense Prior Year369195OtherExpensePriorYear
Other Expenses Current Year534251OtherExpensesCurrentYear
Total Expenses Prior Year5992661TotalExpensesPriorYear
Total Expenses Current Year5888112TotalExpensesCurrentYear
Revenues Less Expenses Prior Year-1583319RevenuesLessExpensesPriorYear
Revenues Less Expenses CY3067281RevenuesLessExpensesCY
Total Assets BOY7543043TotalAssetsBOY
Total Assets EOY10267142TotalAssetsEOY
Total Liabilities BOY369491TotalLiabilitiesBOY
Total Liabilities EOY785648TotalLiabilitiesEOY
Net Assets Or Fund Balances BOY7173552NetAssetsOrFundBalancesBOY
Net Assets Or Fund Balances EOY9481494NetAssetsOrFundBalancesEOY
Mission DescriptionBIOGENOMIC MEDICAL RESEARCH FUNDRAISING FOR THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (TGEN).MissionDescription
Significant New Program ServicesfalseSignificantNewProgramServices
Significant ChangefalseSignificantChange
Expense4259390Expense
Grants4259390Grants
DescriptionSEE SCHEDULE ODescription
Total Program Service Expense4259390TotalProgramServiceExpense
Described In501 C3trueDescribedIn501C3
Schedule B RequiredtrueScheduleBRequired
Political ActivitiesfalsePoliticalActivities
Lobbying ActivitiesfalseLobbyingActivities
Donor Advised FundsfalseDonorAdvisedFunds
Conservation EasementsfalseConservationEasements
Collections Of ArtfalseCollectionsOfArt
Credit CounselingfalseCreditCounseling
Term Or Permanent EndowmentstrueTermOrPermanentEndowments
Balance Sheet Amounts ReportedtrueBalanceSheetAmountsReported
Independent Audit Financial StmtfalseIndependentAuditFinancialStmt
Consolidated Audit Financial StmttrueConsolidatedAuditFinancialStmt
SchoolfalseSchool
Foreign OfficefalseForeignOffice
Foreign ActivitiesfalseForeignActivities
More Than5000 K To OrganizationsfalseMoreThan5000KToOrganizations
More Than5000 K To IndividualsfalseMoreThan5000KToIndividuals
Professional FundraisingfalseProfessionalFundraising
Fundraising ActivitiesfalseFundraisingActivities
GamingfalseGaming
HospitalfalseHospital
Grants To OrganizationstrueGrantsToOrganizations
Grants To IndividualsfalseGrantsToIndividuals
Schedule J RequiredtrueScheduleJRequired
Tax Exempt BondsfalseTaxExemptBonds
Excess Benefit TransactionfalseExcessBenefitTransaction
Prior Excess Benefit TransactionfalsePriorExcessBenefitTransaction
Loan To Officer Or DQPfalseLoanToOfficerOrDQP
Grant To Related PersonfalseGrantToRelatedPerson
Bsnss Rltnshp With OrganizationfalseBsnssRltnshpWithOrganization
Bsnss Rltnshp Thru Family MemberfalseBsnssRltnshpThruFamilyMember
Officer Entity With Bsnss RltnshpfalseOfficerEntityWithBsnssRltnshp
Deductible Non Cash ContributionsfalseDeductibleNonCashContributions
Deductible Contributions Of ArtfalseDeductibleContributionsOfArt
TerminatedfalseTerminated
Partial LiquidationfalsePartialLiquidation
Disregarded EntityfalseDisregardedEntity
Related EntitytrueRelatedEntity
Related Org Controlled EntitytrueRelatedOrgControlledEntity
Transfers To Exempt Non Chrtbl OrgfalseTransfersToExemptNonChrtblOrg
Activities Conducted PartnershipfalseActivitiesConductedPartnership
Schedule O RequiredtrueScheduleORequired
Number Forms Transmitted With10962NumberFormsTransmittedWith1096
Number W2 G Included0NumberW2GIncluded
Compliance With Backup WitholdingtrueComplianceWithBackupWitholding
Number Of Employees0NumberOfEmployees
Unrelated Business IncomefalseUnrelatedBusinessIncome
Foreign Financial AccountfalseForeignFinancialAccount
Prohibited Tax Shelter TransfalseProhibitedTaxShelterTrans
Taxable Party NotificationfalseTaxablePartyNotification
Non Deductible ContributionsfalseNonDeductibleContributions
Quid Pro Quo ContributionsfalseQuidProQuoContributions
Form8282 Property Disposed OffalseForm8282PropertyDisposedOf
Funds To Pay PremiumsfalseFundsToPayPremiums
Premiums PaidfalsePremiumsPaid
Nbr Voting Governing Body Members19NbrVotingGoverningBodyMembers
Number Independent Voting Members16NumberIndependentVotingMembers
Family Or Business RelationshipfalseFamilyOrBusinessRelationship
Delegation Of Management DutiesfalseDelegationOfManagementDuties
Changes To Organizing DocsfalseChangesToOrganizingDocs
Material Diversion Or MisusefalseMaterialDiversionOrMisuse
Members Or StockholderstrueMembersOrStockholders
Election Of Board MemberstrueElectionOfBoardMembers
Decisions Subject To ApprovaltrueDecisionsSubjectToApproval
Minutes Of Governing BodytrueMinutesOfGoverningBody
Minutes Of CommitteestrueMinutesOfCommittees
Officer Mailing AddressfalseOfficerMailingAddress
Local ChaptersfalseLocalChapters
Form990 Provided To Governing BodytrueForm990ProvidedToGoverningBody
Conflict Of Interest PolicytrueConflictOfInterestPolicy
Annual Disclosure Covered PersonstrueAnnualDisclosureCoveredPersons
Regular Monitoring EnforcementtrueRegularMonitoringEnforcement
Whistleblower PolicytrueWhistleblowerPolicy
Document Retention PolicytrueDocumentRetentionPolicy
Compensation Process CEOtrueCompensationProcessCEO
Compensation Process OthertrueCompensationProcessOther
Investment In Joint VenturefalseInvestmentInJointVenture
States Where Copy Of Return Is FiledAZStatesWhereCopyOfReturnIsFiled
Upon RequestXUponRequest

The Books Are In Care Of TheBooksAreInCareOf

FieldValueIRS element (for citing)
Name PersonELIZABETH MONTEMAYORNamePerson
Telephone Number6023438508TelephoneNumber

Address US AddressUS

FieldValueIRS element (for citing)
Address Line1400 E VAN BUREN SUITE 850AddressLine1
CityPHOENIXCity
StateAZState
ZIP Code85004ZIPCode

Form990 Part VII Section A Form990PartVIISectionA (20 entries)

TitleTitleAverage Hours Per WeekAverageHoursPerWeekIndividual Trustee Or DirectorIndividualTrusteeOrDirectorOfficerOfficerReportable Comp From OrganizationReportableCompFromOrganizationReportable Comp From Related OrgsReportableCompFromRelatedOrgsOther CompensationOtherCompensationHighest Compensated EmployeeHighestCompensatedEmployee
MICHAEL BASSOFF
DIRECTOR/PRESIDENT40.0XX043723915791
JOSE CARDENAS
DESIGNATED DIRECTOR/TGEN CHAIR1.0X000
BENNETT DORRANCE
CHAIRMAN/DESIGNATED DIRECTOR1.0XX000
JERRY BISGROVE
DIRECTOR1.0X000
KARL ELLER
DIRECTOR1.0X000
DIANE HALLE
DIRECTOR1.0X000
LEE HANLEY
DIRECTOR1.0X000
MIKE INGRAM
DIRECTOR1.0X000
CATHERINE IVY
DIRECTOR1.0X000
KEN KENDRICK
SECRETARY/DIRECTOR1.0XX000
RICHARD LEHMANN
TREASURER/DIRECTOR1.0XX000
F FRANCIS NAJAFI
DIRECTOR1.0X000
THE HONORABLE SKIP RIMSZA
DIRECTOR1.0X000
RAY THURSTON
DIRECTOR1.0X000
PHIL FRANCIS
DIRECTOR1.0X000
JEFFREY M TRENT PHD
DESIGNATED DIRECTOR/TGEN PRES1.0X0104604617553
TERESA BURLESON
DESIGNATED DIRECTOR/TGEN COO1.0X037513017553
TROY RICHARDS
DIRECTOR1.0X000
HOWARD YOUNG
DIRECTOR1.0X000
DENISE MCCLINTIC
ASSOCIATE VP MAJOR GIFTS40.0016696210071X
FieldValueIRS element (for citing)
Total Reportable Comp From Org0TotalReportableCompFromOrg
Total Reportable Comp Frm Rltd Orgs2025377TotalReportableCompFrmRltdOrgs
Total Other Compensation60968TotalOtherCompensation
Number Individuals GT100 K0NumberIndividualsGT100K
Formers ListedfalseFormersListed
Total Comp GT150 KtrueTotalCompGT150K
Compensation From Other SourcesfalseCompensationFromOtherSources

Contractor Compensation ContractorCompensation

Name Of Contractor NameOfContractor

FieldValueIRS element (for citing)
Name PersonTRANSLATIONAL GENOMICS RESEARCH INSNamePerson

Address Of Contractor AddressOfContractor

Address US AddressUS

FieldValueIRS element (for citing)
Address Line1445 NORTH 5TH STREET STE 600AddressLine1
CityPHOENIXCity
StateAZState
ZIP Code85004ZIPCode
FieldValueIRS element (for citing)
Description Of ServicesMANAGEMENTDescriptionOfServices
Compensation108000Compensation
FieldValueIRS element (for citing)
Number Of Contractors GT100 K2NumberOfContractorsGT100K
All Other Contributions8918909AllOtherContributions
Noncash Contributions12595NoncashContributions
Total Contributions8918909TotalContributions
Total Program Service Revenue0TotalProgramServiceRevenue

Investment Income InvestmentIncome

FieldValueIRS element (for citing)
Total Revenue Column36484TotalRevenueColumn
Exclusion$36,484ExclusionAmount

Income From Invest Bond Proceeds IncomeFromInvestBondProceeds

FieldValueIRS element (for citing)
Total Revenue Column0TotalRevenueColumn

Royalties Revenue RoyaltiesRevenue

FieldValueIRS element (for citing)
Total Revenue Column0TotalRevenueColumn

Net Gain Or Loss Investments NetGainOrLossInvestments

FieldValueIRS element (for citing)
Total Revenue Column0TotalRevenueColumn

Net Income From Fundraising Events NetIncomeFromFundraisingEvents

FieldValueIRS element (for citing)
Total Revenue Column0TotalRevenueColumn

Net Income From Gaming NetIncomeFromGaming

FieldValueIRS element (for citing)
Total Revenue Column0TotalRevenueColumn

Net Income Or Loss NetIncomeOrLoss

FieldValueIRS element (for citing)
Total Revenue Column0TotalRevenueColumn
FieldValueIRS element (for citing)
Total Other Revenue0TotalOtherRevenue

Total Revenue TotalRevenue

FieldValueIRS element (for citing)
Total Revenue Column8955393TotalRevenueColumn
Exclusion$36,484ExclusionAmount

Grants To Domestic Orgs GrantsToDomesticOrgs

FieldValueIRS element (for citing)
Total4259390Total
Program Services4259390ProgramServices

Grants To Domestic Individuals GrantsToDomesticIndividuals

FieldValueIRS element (for citing)
Total0Total

Foreign Grants ForeignGrants

FieldValueIRS element (for citing)
Total0Total

Benefits To Members BenefitsToMembers

FieldValueIRS element (for citing)
Total0Total

Comp Current Officers Directors CompCurrentOfficersDirectors

FieldValueIRS element (for citing)
Total617000Total
Management And General61700ManagementAndGeneral
Fundraising555300Fundraising

Comp Disqual Persons CompDisqualPersons

FieldValueIRS element (for citing)
Total0Total

Other Salaries And Wages OtherSalariesAndWages

FieldValueIRS element (for citing)
Total329659Total
Management And General32966ManagementAndGeneral
Fundraising296693Fundraising

Pension Plan Contributions PensionPlanContributions

FieldValueIRS element (for citing)
Total0Total

Other Employee Benefits OtherEmployeeBenefits

FieldValueIRS element (for citing)
Total147812Total
Management And General14781ManagementAndGeneral
Fundraising133031Fundraising

Payroll Taxes PayrollTaxes

FieldValueIRS element (for citing)
Total0Total

Fees For Services Management FeesForServicesManagement

FieldValueIRS element (for citing)
Total113712Total
Management And General113712ManagementAndGeneral
Fundraising0Fundraising

Fees For Services Legal FeesForServicesLegal

FieldValueIRS element (for citing)
Total5335Total
Management And General5335ManagementAndGeneral
Fundraising0Fundraising

Fees For Services Accounting FeesForServicesAccounting

FieldValueIRS element (for citing)
Total0Total

Fees For Services Lobbying FeesForServicesLobbying

FieldValueIRS element (for citing)
Total0Total

Fees For Services Prof Fundraising FeesForServicesProfFundraising

FieldValueIRS element (for citing)
Total0Total

Fees For Services Invst Mgmnt Fees FeesForServicesInvstMgmntFees

FieldValueIRS element (for citing)
Total0Total

Fees For Services Other FeesForServicesOther

FieldValueIRS element (for citing)
Total15151Total
Management And General15151ManagementAndGeneral
Fundraising0Fundraising

Advertising Advertising

FieldValueIRS element (for citing)
Total33081Total
Management And General3308ManagementAndGeneral
Fundraising29773Fundraising

Office Expenses OfficeExpenses

FieldValueIRS element (for citing)
Total149787Total
Management And General14979ManagementAndGeneral
Fundraising134808Fundraising

Information Technology InformationTechnology

FieldValueIRS element (for citing)
Total0Total

Royalties Royalties

FieldValueIRS element (for citing)
Total0Total

Occupancy Occupancy

FieldValueIRS element (for citing)
Total74383Total
Management And General7438ManagementAndGeneral
Fundraising66945Fundraising

Travel Travel

FieldValueIRS element (for citing)
Total31855Total
Management And General0ManagementAndGeneral
Fundraising31855Fundraising

Travel Entrtnmnt Public Officials TravelEntrtnmntPublicOfficials

FieldValueIRS element (for citing)
Total0Total

Conferences Meetings ConferencesMeetings

FieldValueIRS element (for citing)
Total84272Total
Management And General42136ManagementAndGeneral
Fundraising42136Fundraising

Interest Interest

FieldValueIRS element (for citing)
Total0Total

Payments To Affiliates PaymentsToAffiliates

FieldValueIRS element (for citing)
Total0Total

Depreciation Depletion DepreciationDepletion

FieldValueIRS element (for citing)
Total18112Total
Management And General18112ManagementAndGeneral
Fundraising0Fundraising

Insurance Insurance

FieldValueIRS element (for citing)
Total0Total

Other Expenses OtherExpenses (2 entries)

DescriptionDescriptionTotalTotalManagement And GeneralManagementAndGeneralFundraisingFundraising
SEMINARS AND EDUCATION53935394854
DUES AND SUBSCRIPTIONS317003170

Total Functional Expenses TotalFunctionalExpenses

FieldValueIRS element (for citing)
Total5888112Total
Program Services4259390ProgramServices
Management And General330157ManagementAndGeneral
Fundraising1298565Fundraising

Savings And Temp Cash Investments SavingsAndTempCashInvestments

FieldValueIRS element (for citing)
BOY4985857BOY
EOY5732940EOY

Pledges And Grants Receivable PledgesAndGrantsReceivable

FieldValueIRS element (for citing)
BOY2227657BOY
EOY4362848EOY
FieldValueIRS element (for citing)
Accounts ReceivableAccountsReceivable

Prepaid Expenses Deferred Charges PrepaidExpensesDeferredCharges

FieldValueIRS element (for citing)
EOY13833EOY
FieldValueIRS element (for citing)
Land Buildings Equipment Basis168169LandBuildingsEquipmentBasis
Land Bldg Equipment Accum Deprec153594LandBldgEquipmentAccumDeprec

Land Buildings Equipment Basis Net LandBuildingsEquipmentBasisNet

FieldValueIRS element (for citing)
BOY32687BOY
EOY14575EOY

Investments Pub Traded Securities InvestmentsPubTradedSecurities

FieldValueIRS element (for citing)
BOY285972BOY
EOY68117EOY

Investments Other Securities InvestmentsOtherSecurities

FieldValueIRS element (for citing)
EOY67964EOY

Other Assets Total OtherAssetsTotal

FieldValueIRS element (for citing)
BOY10870BOY
EOY6865EOY

Total Assets TotalAssets

FieldValueIRS element (for citing)
BOY7543043BOY
EOY10267142EOY

Accounts Payable Accrued Expenses AccountsPayableAccruedExpenses

FieldValueIRS element (for citing)
BOY66121BOY
EOY83573EOY

Other Liabilities OtherLiabilities

FieldValueIRS element (for citing)
BOY303370BOY
EOY702075EOY

Total Liabilities TotalLiabilities

FieldValueIRS element (for citing)
BOY369491BOY
EOY785648EOY
FieldValueIRS element (for citing)
Follow SFAS117XFollowSFAS117

Unrestricted Net Assets UnrestrictedNetAssets

FieldValueIRS element (for citing)
BOY1716947BOY
EOY580912EOY

Temporarily Restricted Net Assets TemporarilyRestrictedNetAssets

FieldValueIRS element (for citing)
BOY5394512BOY
EOY8838489EOY

Permanently Restricted Net Assets PermanentlyRestrictedNetAssets

FieldValueIRS element (for citing)
BOY62093BOY
EOY62093EOY

Total Net Assets Fund Balances TotalNetAssetsFundBalances

FieldValueIRS element (for citing)
BOY7173552BOY
EOY9481494EOY

Total Liab Net Assets Fund Balances TotalLiabNetAssetsFundBalances

FieldValueIRS element (for citing)
BOY7543043BOY
EOY10267142EOY
FieldValueIRS element (for citing)
Method Of Accounting AccrualXMethodOfAccountingAccrual
Accountant Compile Or ReviewfalseAccountantCompileOrReview
FS AuditedtrueFSAudited
Audit CommitteetrueAuditCommittee
Financial Statement ConsolidatedXFinancialStatementConsolidated
Federal Grant Audit RequiredfalseFederalGrantAuditRequired

Schedule A IRS990ScheduleA

FieldValueIRS element (for citing)
Publicly Supported Org170b1 AviXPubliclySupportedOrg170b1Avi

Gifts Grants Contrib Received170 GiftsGrantsContribReceived170

FieldValueIRS element (for citing)
Current Tax Year Minus4 Years10836405CurrentTaxYearMinus4Years
Current Tax Year Minus3 Years4804855CurrentTaxYearMinus3Years
Current Tax Year Minus2 Years5598863CurrentTaxYearMinus2Years
Current Tax Year Minus1 Year4359865CurrentTaxYearMinus1Year
Current Tax Year721605CurrentTaxYear
Total26321593Total

Total170 Total170

FieldValueIRS element (for citing)
Current Tax Year Minus4 Years10836405CurrentTaxYearMinus4Years
Current Tax Year Minus3 Years4804855CurrentTaxYearMinus3Years
Current Tax Year Minus2 Years5598863CurrentTaxYearMinus2Years
Current Tax Year Minus1 Year4359865CurrentTaxYearMinus1Year
Current Tax Year721605CurrentTaxYear
Total26321593Total
FieldValueIRS element (for citing)
Amounts Subst Contributors Total9891364AmountsSubstContributorsTotal
Public Support Total17016430229PublicSupportTotal170

Gross Investment Income170 GrossInvestmentIncome170

FieldValueIRS element (for citing)
Current Tax Year Minus4 Years175433CurrentTaxYearMinus4Years
Current Tax Year Minus3 Years250673CurrentTaxYearMinus3Years
Current Tax Year Minus2 Years188867CurrentTaxYearMinus2Years
Current Tax Year Minus1 Year74077CurrentTaxYearMinus1Year
Current Tax Year33934CurrentTaxYear
Total722984Total
FieldValueIRS element (for citing)
Total Support27044577TotalSupport
Public Support Pertcentage1700.60752PublicSupportPertcentage170
Public Support Pertcent Prior Year0.63509PublicSupportPertcentPriorYear
Thirty Three Percnt Tests CY170XThirtyThreePercntTestsCY170

Schedule B IRS990ScheduleB

Contributor Info ContributorInfo

FieldValueIRS element (for citing)
Contributor NumberRESTRICTEDContributorNumber

Contributor Name Business ContributorNameBusiness

FieldValueIRS element (for citing)
Business Name Line1RESTRICTEDBusinessNameLine1

Contributor Address US ContributorAddressUS

FieldValueIRS element (for citing)
Address Line1RESTRICTEDAddressLine1
Address Line2RESTRICTEDAddressLine2
CityRESTRICTEDCity
StateRESTRICTEDState
ZIP CodeRESTRICTEDZIPCode
FieldValueIRS element (for citing)
Aggregate ContributionsRESTRICTEDAggregateContributions

Schedule D IRS990ScheduleD

FieldValueIRS element (for citing)
Art Public Exhibition AmtsArtPublicExhibitionAmts
Held Works Of Art AmtsHeldWorksOfArtAmts

Current Year CurrentYear

FieldValueIRS element (for citing)
Beginning Of Year Balance62093BeginningOfYearBalance
Investment Earnings Or Losses7353InvestmentEarningsOrLosses
Other Expenditures7353OtherExpenditures
End Of Year Balance62093EndOfYearBalance

Current Year Minus1 Year CurrentYearMinus1Year

FieldValueIRS element (for citing)
Beginning Of Year Balance62093BeginningOfYearBalance
Investment Earnings Or Losses6606InvestmentEarningsOrLosses
Other Expenditures6606OtherExpenditures
End Of Year Balance62093EndOfYearBalance
FieldValueIRS element (for citing)
Permanent Endowment EOY Balance1.00000PermanentEndowmentEOYBalance
Endowments Held By Unrelated OrgsfalseEndowmentsHeldByUnrelatedOrgs
Endowments Held By Related OrgstrueEndowmentsHeldByRelatedOrgs
Are Related Orgs Listed Schedule RtrueAreRelatedOrgsListedScheduleR
LandLand
BuildingsBuildings

Leasehold Improvements LeaseholdImprovements

FieldValueIRS element (for citing)
Other Cost Or Other Basis11053OtherCostOrOtherBasis
Depreciation11053Depreciation
Book Value0BookValue

Equipment Equipment

FieldValueIRS element (for citing)
Other Cost Or Other Basis40791OtherCostOrOtherBasis
Depreciation40791Depreciation
Book Value0BookValue

Other Land Buildings OtherLandBuildings

FieldValueIRS element (for citing)
Other Cost Or Other Basis116325OtherCostOrOtherBasis
Depreciation101750Depreciation
Book Value14575BookValue
FieldValueIRS element (for citing)
Total Of Book Value Land Buildings14575TotalOfBookValueLandBuildings
Federal Income Tax Liability0FederalIncomeTaxLiability

Other Liabilities OtherLiabilities

FieldValueIRS element (for citing)
DescriptionDUE TO/FROM TGENDescription
Amount$702,075Amount
FieldValueIRS element (for citing)
Total Of Amounts702075TotalOfAmounts

Form990 Schedule D Part XIV Form990ScheduleDPartXIV (2 entries)

IdentifierIdentifierReturn ReferenceReturnReferenceExplanationExplanation
SCHEDULE D, PART VSUPPLEMENTAL INFORMATION - ENDOWMENTSTHE INSTITUTE'S POLICY FOR APPROPRIATING THE DISTRIBUTION OF ITS SUMMER INTERNSHIP PROGRAM ENDOWMENT HAS BEEN DESIGNED TO SUPPORT A SPECIFIC NUMBER OF SUMMER INTERNS EACH YEAR FOR THE NEXT 25 YEARS. THE INSTITUTE CONSIDERED THE LONG-TERM EXPECTED RETURN ON ITS ENDOWMENT. THE INSTITUTE CLASSIFIES AS PERMANENTLY RESTRICTED NET ASSETS (1) THE ORIGINAL VALUE OF THE GIFT DONATED TO THE PERMANENT ENDOWMENT, (2) THE ORIGINAL VALUE OF SUBSEQUENT GIFTS TO THE PERMANENT ENDOWMENT, AND (3) ACCUMULATIONS TO THE PERMANENT ENDOWMENT MADE IN ACCORDANCE WITH THE DIRECTION OF THE APPLICABLE DONOR GIFT INSTRUMENT.
SCHEDULE D, PART X - FIN 48 FOOTNOTEIN FISCAL 2009, THE INSTITUTE ADOPTED A "MORE LIKELY THAN NOT" THRESHOLD FOR FINANCIAL STATEMENT RECOGNITION AND MEASUREMENT OF AN UNCERTAIN TAX POSITION TAKEN OR EXPECTED TO BE TAKEN IN A TAX RETURN. THE INSTITUTE RECOGNIZES INTEREST AND PENALTIES RELATED TO UNCERTAIN TAX POSITIONS IN OTHER EXPENSES, IF THEY EXIST. THE ADOPTION OF THE MORE LIKELY THAN NOT THRESHOLD FOR FINANCIAL STATEMENT RECOGNITION AND MEASUREMENT OF UNCERTAIN TAX POSITIONS HAD NO SIGNIFICANT IMPACT ON THE INSTITUTE'S CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED JUNE 30, 2010 AND 2009.

Schedule I IRS990ScheduleI

FieldValueIRS element (for citing)
Records MaintainedtrueRecordsMaintained

Recipient Table RecipientTable

Recipient Name Business RecipientNameBusiness

FieldValueIRS element (for citing)
Business Name Line1THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTEBusinessNameLine1

Address US AddressUS

FieldValueIRS element (for citing)
Address Line1445 N 5TH STREET SUITE 600AddressLine1
CityPHOENIXCity
StateAZState
ZIP Code85004ZIPCode
FieldValueIRS element (for citing)
EIN Of Recipient753065445EINOfRecipient
IRC Section501(C)(3)IRCSection
Amount Of Cash Grant4259390AmountOfCashGrant
Purpose Of GrantSUPPORT GENOMICS RESEARCHPurposeOfGrant
FieldValueIRS element (for citing)
Total Nbr Of501 C3 And Govt Grants1TotalNbrOf501C3AndGovtGrants
Total Nbr Of Other Organizations0TotalNbrOfOtherOrganizations

Form990 Schedule I Part IV Form990ScheduleIPartIV

FieldValueIRS element (for citing)
IdentifierSCHEDULE I, PART I, LINE 2Identifier
Return ReferencePROCESS FOR MONITORING USE OF GRANT FUNDS IN THE U.S.ReturnReference
ExplanationTHE FOUNDATION IS ORGANIZED EXCLUSIVELY TO BENEFIT TGEN, A RELATED 501(C)(3) TAX-EXEMPT ORGANIZATION, BY SUPPORTING TGEN'S FUNDRAISING AND DEVELOPMENT FUNCTIONS.Explanation

Schedule J IRS990ScheduleJ

FieldValueIRS element (for citing)
First Class Or Charter TravelXFirstClassOrCharterTravel
Club Dues Or FeesXClubDuesOrFees
Written Policy Re T And E ExpensestrueWrittenPolicyReTAndEExpenses
Substantiation RequiredtrueSubstantiationRequired
Compensation CommitteeXCompensationCommittee
Independent ConsultantXIndependentConsultant
Compensation SurveyXCompensationSurvey
Board Or Committee ApprovalXBoardOrCommitteeApproval
Severance PaymentfalseSeverancePayment
Supplemental Nonqual Retire PlanfalseSupplementalNonqualRetirePlan
Equity Based Comp ArrangementfalseEquityBasedCompArrangement
Comp Based On Revenue Of Filing OrgfalseCompBasedOnRevenueOfFilingOrg
Comp Based On Revenue Related OrgsfalseCompBasedOnRevenueRelatedOrgs
Comp Based Net Earnings Filing OrgfalseCompBasedNetEarningsFilingOrg
Comp Based Net Earnings Relate OrgsfalseCompBasedNetEarningsRelateOrgs
Any Non Fixed PaymentsfalseAnyNonFixedPayments
Initial Contract ExceptionfalseInitialContractException

Form990 Schedule J Part II Form990ScheduleJPartII (4 entries)

Base Compensation Filing OrgBaseCompensationFilingOrgComp Based On Related OrgsCompBasedOnRelatedOrgsBonus Filing OrgBonusFilingOrgBonus Related OrgsBonusRelatedOrgsOther Compensation Filing OrgOtherCompensationFilingOrgOther Compensation Related OrgsOtherCompensationRelatedOrgsDeferred Comp Filing OrgDeferredCompFilingOrgDeferred Comp Related OrgsDeferredCompRelatedOrgsNontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgNontaxable Benefits Related OrgsNontaxableBenefitsRelatedOrgsTotal Compensation Filing OrgTotalCompensationFilingOrgTotal Compensation Related OrgsTotalCompensationRelatedOrgsComp Report Prior990 Filing OrgCompReportPrior990FilingOrgComp Report Prior990 Related OrgsCompReportPrior990RelatedOrgs
MICHAEL BASSOFF
0415239000220000980005991045303000
DENISE MCCLINTIC
015909800078640629203779017703300
JEFFREY M TRENT PHD
0746703023268506665809800077530106359900
TERESA BURLESON
03343540242760165000980007753039268300

Form990 Schedule J Part III Form990ScheduleJPartIII (2 entries)

IdentifierIdentifierExplanationExplanation
SCHEDULE J, PART I, LINE 1AFIRST CLASS TRAVEL IS PERMITTED BY EXECUTIVE STAFF ONLY AND MUST, PER TGEN POLICY, BE PRE-APPROVED BY THE CHIEF OPERATING OFFICER. TGEN DOES PROVIDE MEMBERSHIP TO DR. TRENT AT THE PARADISE VALLEY COUNTRY CLUB. THIS EXPENSE WAS PRE-APPROVED BY THE CHIEF OPERATING OFFICER. THESE EXPENSES WERE NOT CONSIDERED AS TAXABLE COMPENSATION TO THE RECIPIENT.
SCHEDULE J, PART I, LINE 7SOME OF THE PERSONS LISTED IN FORM 990, PART VII WERE PAID BONUSES WHICH WERE BASED ON ACCOMPLISHMENTS OF SPECIFIC MILESTONES AND/OR PERFORMANCE BASES.

Schedule O IRS990ScheduleO

General Explanation GeneralExplanation (12 entries)

IdentifierIdentifierReturn ReferenceReturnReferenceExplanationExplanation
FORM 990, PART III, LINE 4PROGRAM SERVICE ACCOMPLISHMENTSTHE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE FOUNDATION RAISES FUNDS FOR THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (TGEN). THE PROGRAM SERVICE ACCOMPLISHMENTS OF TGEN ARE LISTED BELOW: INTRODUCTION TGEN RESEARCH MOVED FORWARD IN FY10 AT A PACE FAR GREATER THAN ANY PREVIOUS YEAR. THIS NARRATIVE PROVIDES AN OVERVIEW OF THESE SUCCESSES AND REINFORCES OUR MISSION OF DETERMINING THE ROOT GENETIC CAUSES OF NUMEROUS DISEASES AND DISORDERS AND THEN CONVERTING THAT KNOWLEDGE AS QUICKLY AS POSSIBLE INTO DIAGNOSTIC TESTS AND THERAPEUTICS FOR IMPROVED PATIENT CARE. OUR RESEARCH COLLABORATIONS WERE MANY AND VARIED IN TERMS OF BREADTH AND SCOPE AND LOCATION - MANY LOCALLY, OTHERS NATIONALLY AND GLOBALLY. LOCALLY, OUR COLLABORATIONS WITH BANNER HEALTH, MAYO CLINIC, SCOTTSDALE HEALTHCARE, BANNER RESEARCH INSITUTE AND OTHER HOSPITALS AND HEALTH CARE PROVIDERS FOCUSED ON NUMEROUS TYPES OF CANCER, NEUROLOGIC IMPAIRMENTS, AND METABOLIC DISORDERS. TGEN'S RESEARCH HAD A PRESENCE ACROSS THE STATE. THIS INCLUDED OUR ONGOING EFFORTS TO ASSIST THE ARIZONA DEPARTMENT OF HEALTH SERVICES (ADHS) WITH STATE-OF-THE-ART TESTING FOR THE H1N1 SWINE FLU, LOOKING FOR WAYS TO HELP TRACK DRUG-RESISTANT MUTATIONS, FIND NEW TREATMENTS AND AVOID A PANDEMIC. TGEN FACULTY PRESENTED DETAILS ABOUT TGEN'S TEST IN EARLY NOVEMBER 2009 AT THE 47TH ANNUAL MEETING OF THE INFECTIOUS DISEASES SOCIETY OF AMERICA (IDSA) IN PHILADELPHIA. THE H1N1 WORK OCCURRED IN OUR FLAGSTAFF FACILITY, TGEN NORTH, WHILE TO THE SOUTH, TGEN AND THE UNIVERSITY OF ARIZONA ESTABLISHED THE SOUTHWEST COMPREHENSIVE CENTER FOR DRUG DISCOVERY AND DEVELOPMENT THROUGH A $7.5 MILLION NIH GRANT. THE NEW CENTER WILL ALLEVIATE BOTTLENECKS THAT EXIST BETWEEN THE LABORATORY-BASED DISCOVERY OF PROMISING THERAPEUTIC TARGETS AND THE ULTIMATE GOAL OF DELIVERING NEW, SAFE AND EFFECTIVE DRUGS TO ADDRESS UNMET MEDICAL NEEDS OF THE PATIENT. LOCALLY, TGEN'S WORK WITH ASU INCLUDED THE PARTNERSHIP FOR PERSONALIZED MEDICINE, WHICH CONTINUED TO DEVELOP A ROBUST PROTEOMICS APPROACH TO MEDICINE AND HEALTH CARE, AND BUILDING OUT A SUPERCOMPUTER INFRASTRUCTURE THAT RANKS AMONG THE FASTEST IN THE BIOMEDICAL SCIENCES. IN EARLY FEBRUARY 2010, TGEN ANNOUNCED THE COMPLETION OF A STRATEGIC ALLIANCE AND AFFILIATION AGREEMENT WITH THE VAN ANDEL RESEARCH INSTITUTE (VARI) THAT WILL MAXIMIZE THE RESEARCH CAPABILITIES OF BOTH NON-PROFIT INSTITUTES. TGEN EXPECTS THE AGREEMENT TO CREATE A ROBUST BASIC-SCIENCE-TO-TRANSLATIONAL DELIVERY PLATFORM AIMED AT DEVELOPING NEW TESTS AND TREATMENTS FOR PATIENT BENEFIT. TGEN'S FINAL CONTRACT REVISION, SIGNED JANUARY 15, ENABLED THE ARIZONA BIOMEDICAL RESEARCH COMMISSION (ABRC) TO CONTINUE FUNDING TGEN THROUGH STATE TOBACCO-TAX REVENUES. THE NEW STATE CONTRACT, FACILITATED THROUGH ABRC LEADERSHIP AND THE ARIZONA ATTORNEY GENERAL'S OFFICE, ENSURES CONTINUED STATE FUNDING THROUGH FISCAL YEAR 2012. TGEN, THROUGH ITS AFFILIATION WITH SCOTTSDALE HEALTHCARE, INITIATED A NUMBER OF CLINICAL TRIALS FOCUSED ON NUMEROUS TYPES OF CANCER. CLINICAL TRIALS DETERMINE THE ACTIONS OF DRUGS IN HUMANS BY IDENTIFYING THE SIDE EFFECTS ASSOCIATED WITH INCREASING DOSES AND PROVIDING EVIDENCE OF EFFECTIVENESS. IN SEPTEMBER 2009, TGEN PUBLISHED ITS SECOND INDEPENDENT, THIRD PARTY ECONOMIC IMPACT REPORT, WHICH PROVIDED ENCOURAGING RESULTS IN TERMS OF TGEN AS A POSITIVE RETURN ON THE STATE INVESTMENT. WE FOLLOWED THAT REPORT IN JANUARY 2010 WITH THE PUBLICATION OF OUR FIRST INDEPENDENT ANALYSIS OF THE ECONOMIC IMPACT OF TGEN DRUG DEVELOPMENT (TD2) ON EMPLOYMENT, REVENUES AND BUSINESS DEVELOPMENT IN SCOTTSDALE. ADDITIONALLY, A DESCRIPTION OF PEER REVIEWED PUBLICATION, GRANT, CONTRACT, PHILANTHROPIC, EDUCATIONAL AND MEDIA ACTIVITY FOLLOWS. PEER-REVIEWED LABORATORY RESEARCH PUBLICATIONS AND PRESENTATIONS SINCE ITS INCEPTION, THE RESEARCH AND CLINICAL ASPECTS OF TGEN HAVE FOCUSED SOLELY ON THE PATIENT AS AN END POINT. AT TGEN, OUR FACULTY WORK TO DISCOVER THE UNDERLYING CAUSE OF DISEASE PROGRESSION AND RESISTANCE TO THERAPY AND WHY SOME INDIVIDUALS ENCOUNTER DEBILITATING DISEASES AND OTHERS LIVE HEALTHY LIVES. OUR CLINICAL TRIALS -IN COLLABORATION WITH SCOTTSDALE HEALTHCARE- NOT ONLY OFFER HOPE TO PATIENTS SUFFERING FROM MANY TYPES OF CANCER, THE RESULTS SERVE TO INFORM OUR RESEARCH STUDIES. SUPPORTED BY A NEW WAVE OF TECHNOLOGY, TGEN'S RESEARCH AND CLINICAL EFFORTS REMAIN EQUAL TO THE STRENGTHS AND CAPABILITIES OF ANY OF TODAY'S LEADING RESEARCH AND CLINICAL INSTITUTES. NOWHERE IS THIS MORE EVIDENT THAN WITH TGEN'S SEQUENCING CAPABILITIES. TGEN HAS "CENTER OF EXCELLENCE" STATUS WITH THREE OF THE WORLD'S LARGEST GENOMICS TECHNOLOGY PROVIDERS - AFFYMETRIX, AGILENT AND LIFE TECHNOLOGIES. TGEN'S NEXT-GENERATION OR "NEXT-GEN" SEQUENCING, SYSTEMS ALLOW US TO DIG DEEPER INTO THE GENOME THAN EVER BEFORE BY PROVIDING MORE INFORMATION AND INCREASING OUR PROBABILITY OF IDENTIFYING SOMETHING SIGNIFICANT. THE LONG-TERM HOPE IS THAT DOCTORS WILL LEVERAGE THIS INFORMATION TO INFORM DECISIONS ABOUT PATIENT CARE. A MAJOR INITIATIVE CENTERS ON CANINE GENETICS. THE PROGRAM FOR CANINE HEALTH AND PERFORMANCE (PCHP) IS A TGEN/VARI INTER-INSTITUTIONAL PROGRAM DEVELOPED TO ACCELERATE THE PATH TO DISCOVERY OF CAUSATIVE GENETIC LESIONS ACROSS SEVERAL DISEASES IN DOGS THAT SIMILARLY AFFLICT HUMANKIND (INCLUDING CANCER, DEAFNESS, MULTIPLE SCLEROSIS, HEART DEFECTS, OBESITY, NEUROLOGIC DISORDERS AND OTHERS). AN IMPORTANT PART OF THE PCHP IS THE CANINE HEREDITARY CANCER CONSORTIUM (CHCC), WHICH WAS A RECENTLY FUNDED AARA NATIONAL CANCER INSTITUTE AWARD TO TGEN. TGEN, THE VAN ANDEL RESEARCH INSTITUTE (VARI) AND THE NATIONAL CANCER INSTITUTE LAUNCHED THE CHCC TO STUDY NATURALLY OCCURRING CANCERS IN DOGS TO BETTER UNDERSTAND WHY BOTH PETS AND PEOPLE GET SICK. TGEN'S RESEARCH RESULTS APPEAR IN A NUMBER OF SCIENTIFIC AND MEDICAL JOURNALS, AND ADD TO THE GROWING KNOWLEDGE BASE OF MOLECULAR RESEARCH AND MEDICINE. IN FY10, TGEN RESEARCHERS PUBLISHED THEIR RESEARCH RESULTS IN NUMEROUS SCHOLARLY PEER-REVIEWED ACADEMIC JOURNALS AND THROUGH PRESENTATIONS AT LEADING NATIONAL AND INTERNATIONAL CONFERENCES. THESE INCLUDE PUBLICATION IN LEADING SCIENTIFIC JOURNALS SUCH AS NEW ENGLAND JOURNAL OF MEDICINE, NATURE GENETICS, PLOS, BLOOD, CANCER RESEARCH, AND A HOST OF OTHER DISEASE-ASSOCIATED PUBLICATIONS (E.G. DIABETES, MOLECULAR CANCER THERAPEUTICS, NEUROLOGY, JOURNAL OF WOMEN'S HEALTH, ETC.)
SELECT HIGHLIGHTS FOR FY101. TGEN AND UC BERKELEY RESEARCHERS REPORTED IN THE JULY 20 NATURE GENETICS IDENTIFICATION OF A GENE VARIANT THAT CARRIES NEARLY TWICE THE RISK OF DEVELOPING AN INCREASINGLY COMMON TYPE OF BLOOD CANCER. INVESTIGATORS FOUND THAT MUTATIONS IN A GENE CALLED C6ORF15, OR STG, ARE ASSOCIATED WITH THE RISK OF DEVELOPING FOLLICULAR LYMPHOMA. THIS IS A CANCER OF THE BODY'S DISEASE-FIGHTING NETWORK WHOSE RATES HAVE NEARLY DOUBLED IN THE PAST THREE DECADES. CITATION: GENETIC VARIANTS AT 6P21.33 INFLUENCE FOLLICULAR LYMPHOMA RISK CHRISTINE F. SKIBOLA, PAIGE M. BRACCI, ERAN HALPERIN, LUCIA CONDE, DAVID W. CRAIG, LUZ AGANA, KELLY IYADURAI, NIKOLAUS BECKER, ANGELA BROOKES-WILSON, JOHN D. CURRY, JOHN SPINELLI, ELIZABETH A. HOLLY, JACQUES RIBY, LUOPING ZHANG, ALEXANDRA NIETERS, MARTYN T. SMITH, KEVIN M. BROWN. NATURE GENETICS 41, 873-875 (20 JULY 2009) 2. ANALYSES OF CLINICAL TRIAL RESULTS, PUBLISHED SEPTEMBER 2 IN THE NEW ENGLAND JOURNAL OF MEDICINE, SHOW A POTENTIAL NEW INVESTIGATIONAL THERAPY FOR ADVANCED AND METASTATIC BASAL CELL SKIN CANCER. THE STUDY, CONDUCTED AT TGEN CLINICAL RESEARCH SERVICE (TCRS) AT SCOTTSDALE HEALTHCARE AND TWO OTHER SITES APPEARS TO DEMONSTRATE TUMOR SHRINKAGE AND LIMITED SIDE EFFECTS. THESE FINDINGS ARE SIGNIFICANT BECAUSE NO PROVEN THERAPY EXISTS FOR ADVANCED BASAL CELL CARCINOMA (BCC). BCC IS THE MOST COMMON CANCER IN THE UNITED STATES WITH ABOUT ONE MILLION NEW CASES DIAGNOSED EACH YEAR. ARIZONA HAS ONE OF THE HIGHEST INCIDENCES OF SKIN CANCER IN THE WORLD. CITATION: INHIBITION OF THE HEDGEHOG PATHWAY IN ADVANCED BASAL-CELL CARCINOMA DANIEL D. VON HOFF, M.D., PATRICIA M. LORUSSO, D.O., CHARLES M. RUDIN, M.D., PH.D., JOSINA C. REDDY, M.D., PH.D., ROBERT L. YAUCH, PH.D., RAOUL TIBES, M.D., GLEN J. WEISS, M.D., MITESH J. BORAD, M.D., CHRISTINE L. HANN, M.D., PH.D., JULIE R. BRAHMER, M.D., HOWARD M. MACKEY, PH.D., BERTRAM L. LUM, PHARM.D., WALTER C. DARBONNE, M.S., JAMES C. MARSTERS, JR., PH.D., FREDERIC J. DE SAUVAGE, PH.D., AND JENNIFER A. LOW, M.D., PH.D. PUBLISHED AT WWW.NEJM.ORG SEPT. 2, 2009 3. TGEN CLINICAL RESEARCH SERVICES AT SCOTTSDALE HEALTHCARE ANNOUNCED SEPTEMBER 22 THE START OF A CLINICAL TRIAL FOR A DRUG DESIGNED TO COMBAT ADRENOCORTICAL CARCINOMA (ACC), A RARE BUT DEADLY CANCER THAT ATTACKS THE ADRENAL GLANDS. OTHER THAN SURGERY, THE ONLY TREATMENT FOR ACC IS THE EXACTING USE OF A COMPOUND CALLED MITOTANE, A CHEMICAL RELATIVE OF DDT, WHICH THE U.S. BANNED AS AN INSECTICIDE IN 1972. 4. DR. GLEN WEISS OF TGEN AND SCOTTSDALE HEALTHCARE IN JULY ANNOUNCED TWO SIGNIFICANT ADVANCES IN TREATING LUNG CANCER. DR. WEISS, AN ASSOCIATE INVESTIGATOR IN TGEN'S CANCER AND CELL BIOLOGY DIVISION AND DIRECTOR OF THORACIC ONCOLOGY AT TGEN CLINICAL RESEARCH SERVICES AT SCOTTSDALE HEALTHCARE, MADE BOTH ANNOUNCEMENTS AT THE 13TH WORLD CONFERENCE ON LUNG CANCER IN SAN FRANCISCO, OCTOBER 2009. 5. A SCIENTIFIC PAPER ABOUT USING MICRORNAS, SMALL MOLECULES THAT REGULATE GENE EXPRESSION IN CELLS, TO HELP UNDERSTAND AND PREDICT HOW MALIGNANT LUNG CANCER OFTEN SPREADS TO THE BRAIN. THIS PAPER WAS SELECTED AS THE BEST OF 233 SCIENTIFIC PAPERS AT THE INSTITUTE OF ELECTRICAL AND ELECTRONICS ENGINEERS INTERNATIONAL CONFERENCE ON BIOINFORMATICS & BIOMEDICINE, HELD NOV. 1-4 IN WASHINGTON, D.C. CITATION: IDENTIFYING MIRNA AND IMAGING FEATURES ASSOCIATED WITH METASTASIS OF LUNG CANCER TO THE BRAIN - SARA NASSER, AARATI R. RANADE, SHRAVAN SRIDHART, LISA HANEY, RONALD L. KORN, MICHAEL B. GOTWAY, GLEN J. WEISS, SEUNGCHAN KIM. 6. A STUDY PUBLISHED IN THE DECEMBER EDITION OF DIABETIC MEDICINE, SHOWED IT IS POSSIBLE TO IDENTIFY BIOMARKERS ASSOCIATED WITH END-STAGE RENAL DISEASE (ESRD) FROM THE POOLED DNA OF MORE THAN 1,000 DIABETICS. SPECIFICALLY, TGEN RESEARCHERS IDENTIFIED GENES THAT COULD POTENTIALLY CONTRIBUTE TO ESRD AMONG THOSE WITH TYPE 1 DIABETES. CITATION: IDENTIFICATION OF SPECIFIC DNA VARIANTS MAY ENHANCE OUR UNDERSTANDING OF GENETIC RISK FACTORS FOR RENAL DISEASE AND MAY PROVIDE DIAGNOSTIC VALUE IN DETERMINING WHICH PATIENTS ARE AT GREATEST RISK OF DEVELOPING ESRD - DAVID W. CRAIG, MEREDITH P. MILLIS AND JOHANNA K. DISTEFANO. 7. AS PART OF AN OVERALL EFFORT BY THE NATIONAL INSTITUTES OF HEALTH TO IDENTIFY ALL MICROBIOMS ON AND IN THE HUMAN BODY, TGEN CONDUCTED A STUDY IN CONJUNCTION WITH JOHNS HOPKINS UNIVERSITY PUBLISHED JAN. 6 BY THE SCIENTIFIC JOURNAL PLOS ONE, WHICH DOCUMENTED FOR THE FIRST TIME THE DRAMATIC CHANGES IN BACTERIAL COMMUNITIES FOLLOWING CIRCUMCISION AND THE POSSIBLE EFFECTS ON HIV INFECTION. CITATION: THE EFFECTS OF CIRCUMCISION ON THE PENIS MICROBIOME - LANCE B. PRICE, CINDY M. LIU, KRISTINE E. JOHNSON, MALIHA AZIZ, MATTHEW K. LAU, JOLENE BOWERS, JACQUES RAVEL, PAUL S. KEIM, DAVID SERWADDA, MARIA J. WAWER AND RONALD H. GRAY. 8. A STUDY IN CONJUNCTION WITH SCOTTSDALE HEALTHCARE - AND WITH THE HELP OF SCIENTISTS AT THE VAN ANDEL RESEARCH INSTITUTE - SHOWED HOW TO PREDICT WHICH PATIENTS WITH SMALL-CELL LUNG CANCER MAY BE RESISTANT TO FIRST-LINE CHEMOTHERAPY. THIS STUDY WAS PRESENTED IN JANUARY IN SAN DIEGO AT THE AACR-IASLC'S JOINT CONFERENCE ON MOLECULAR ORIGINS OF LUNG CANCER. CITATION: TUMOR MICRORNA BIOMARKERS ASSOCIATED WITH DE NOVO CHEMORESISTANCE IN SMALL CELL LUNG CANCER - GLEN J. WEISS, AARATI R. RANADE, DAVID CHERBA, SHRAVAN SRIDHAR, PATRICK RICHARDSON, ANOOR PARIPATI, BRAD BOWLES AND CRAIG WEBB. 9. AS PART OF A MULTI-YEAR STUDY IN CONJUNCTION WITH THE ARIZONA ALZHEIMER'S CONSORTIUM, TGEN SCIENTISTS PUBLISHED A PAPER IN THE JANUARY EDITION OF BMC GENOMICS, SHOWING HOW THREE KINASES, OR PROTEINS, DISMANTLE CONNECTIONS WITHIN BRAIN CELLS, WHICH MAY LEAD TO MEMORY LOSS ASSOCIATED WITH ALZHEIMER'S DISEASE. CITATION: HIGH-CONTENT SIRNA SCREENING OF THE "KINOME" IDENTIFIES EIF2AK2 AND DYRK1A AS CRITICAL MEDIATORS OF AD-RELATED TAU HYPERPHOSPHORYLATION - AZORSA, ROBESON, FROST, MEECHOOVET, BRAUTIGAM, DICKEY, BEAUDRY, BASU, HOLZ, HERNANDEZ, BISANZ, GWINN, GROVER, ROGERS, REIMAN, HUTTON, STEPHAN, MOUSSES AND DUNCKLEY. 10. TGEN WAS PART OF A NATIONAL CONSORTIUM THAT CONDUCTED THE LARGEST GENOME-WIDE ASSOCIATION STUDY IN ALZHEIMER'S DISEASE TO DATE, IDENTIFYING TWO NEW GENETIC VARIANTS AND CONFIRMING TWO OTHERS. THEIR FINDINGS WERE PUBLISHED MAY 12 IN THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION. CITATION: SESHADRI S, ET AL "GENOME-WIDE ANALYSIS OF GENETIC LOCI ASSOCIATED WITH ALZHEIMER DISEASE" JAMA 2010; 303: 1832-40. 11. DR. DANIEL D. VON HOFF, TGEN'S PHYSICIAN-IN-CHIEF, RECEIVED A TOP AWARD FROM THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) FOR HIS CANCER RESEARCH. DR. VON HOFF RECEIVED THE 2010 DAVID A. KARNOFSKY MEMORIAL AWARD AND LECTURE AT ASCO'S 46TH ANNUAL MEETING THIS PAST WEEK (JUNE 4-8) AT THE MCCORMICK PLACE IN CHICAGO. ASCO PRESENTED THE AWARD TO DR. VON HOFF "FOR HIS OUTSTANDING ACHIEVEMENTS IN CANCER RESEARCH AND FOR HIS IMPACT ON THE TREATMENT OF PATIENTS WITH CANCER." CITATION: ANALYSIS OF SOMATIC COPY NUMBER ALTERATIONS ASSOCIATED WITH POOR PROGNOSIS AND PROGRESSION OF MULTIPLE MYELOMA IN AFRICAN AMERICANS. 12. TGEN SCIENTISTS HAVE IDENTIFIED FIVE GENETIC BIOMARKERS THAT COULD HELP LEAD TO IMPROVED TREATMENTS, WITH FEWER SIDE EFFECTS, FOR PATIENTS WITH DIABETES. TGEN SENIOR INVESTIGATOR DR. JOHANNA DISTEFANO PRESENTED THE FINDINGS IN NEW ORLEANS ON JUNE 6, 2010, AT THE 69TH SCIENTIFIC SESSIONS OF THE AMERICAN DIABETES ASSOCIATION. CITATION: IMPROVED INSULIN SENSITIVITY (SI), A PRIMARY RESPONSE TO THIAZOLIDINEDIONE (TZD) THERAPY, VARIES AMONG TREATED INDIVIDUALS. AMERICAN DIABETES ASSOCIATION.
CLINICAL RESEARCHESTABLISHED IN 2006, TGEN CLINICAL RESEARCH SERVICES (TCRS), A STRATEGIC ALLIANCE WITH SCOTTSDALE HEALTHCARE (SHC), PROVIDES A DIRECT CLINICAL RESEARCH SITE FOR TGEN. TCRS BRINGS NEW CLINICAL RESEARCH INTO THE COMMUNITY, TO THOSE PATIENTS WHO WOULD OTHERWISE HAVE TO TRAVEL SOMEPLACE ELSE FOR ACCESS TO NEW THERAPIES OR PREVENTION AGENTS. THESE CLINICAL TRIALS GIVE OPTIONS THAT DID NOT EXIST BEFORE TO PHOENIX-AREA PATIENTS AS WELL AS PATIENTS FROM ALL OVER THE COUNTRY. TCRS CLINICIAN, UNDER THE DIRECTION TGEN PHYSICIAN-IN-CHIEF DR. DANIEL VON HOFF, FOCUS ON CLINICAL TRIALS WITH TARGETED AGENTS AND GENOMICS-BASED INDIVIDUALIZED THERAPY. TCRS WORKS IN COLLABORATION WITH PHYSICIANS IN THE LOCAL ARIZONA COMMUNITY AND ACROSS THE U.S. TO PROVIDE OPTIONS FOR THE CARE OF THEIR PATIENTS. TCRS SERVES AS AN INTERNATIONAL REFERRAL CENTER FOR PATIENTS FROM ANYWHERE IN THE WORLD. EVERY PATIENT WITH A PHYSICIAN REFERRAL IS WELCOME, PROVIDED THEY MEET THE REQUIREMENTS. IN SOME CASES, THE PATIENT MAY BE EVALUATED THROUGH THE NEW CLINIC, BUT RECEIVE TREATMENT FROM THEIR REFERRING PHYSICIAN. WE WORK FLEXIBLY TO ENSURE THE BEST AND MOST COMPLETE CARE FOR PATIENTS. PATIENT PARTICIPATION IN CLINICAL TRIALS AT TCRS - 125 VISITS PER MONTH - 35-45 NEW PATIENTS PER MONTH - 400-600 PATIENT SAMPLES COLLECTED PER MONTH GRANT SUPPORT GRANT FUNDING IS OFTEN THE LIFEBLOOD OF RESEARCH. IN FY09, TGEN INVESTIGATORS SUBMITTED 149 GRANTS TOTALING $160,926,066. TGEN WAS AWARDED 15 GRANTS, TOTALING $9,256,581, WITH AN ADDITIONAL 64 GRANTS PENDING AND IN REVIEWS TOTALING $54,142,798. ADDITIONALLY, TGEN RECEIVED $29,844,531 FROM PREVIOUS FY PENDING GRANTS, BRINGING THE AWARDED TOTAL FOR FY09 TO $39,101,112. TGEN'S SUCCESS RATE CURRENTLY RESTS AT 26 PERCENT OF TOTAL GRANTS SUBMITTED, PLACING THE INSTITUTE NEARLY SIX PERCENT HIGHER THAN THE NATIONAL AVERAGE (NIH OVERALL SUCCESS RATE). FY10 HIGHLIGHTS 1. A 5-YEAR NIH GRANT, TOTALING $4,059,520 TO DR. DAVID DUGGAN FOR A WECARE GENOME-WIDE ASSOCIATION STUDY OF RADIATION EXPOSURE AND BILATERAL BREAST CANCER. 2. A 2-YEAR NIH GRANT, TOTALING $1,887,446 TO DR. DUGGAN FOR FOLLOW-UP STUDIES ABOUT GENETICALLY DETERMINED RISK FACTORS FOR HIP FRACTURES. 3. A 5-YEAR NIH GRANT, TOTALING $1,532,579 TO DR. DUGGAN FOR A STUDY OF INFLAMMATION AND THROMBOSIS GENE PATHWAYS AND CARDIOVASCULAR DISEASE. 4. A 3-YEAR NIH GRANT, TOTALING $2,065,512 TO JOHN PEARSON FOR AN IN SILICO CENTER OF EXCELLENCE. 5. A 2-YEAR NIH GRANT, TOTALING $416,780, TO DR. PAUL KEIM FOR GENOMICS-BASED DIAGNOSTICS FOR COCCIDIOIDES, THE CAUSATIVE AGENTS OF VALLEY FEVER. 6. A 2-YEAR GRANT TOTALING $1,000,000 FROM THE MELANOMA RESEARCH ALLIANCE TO DR. JEFFREY TRENT FOR THE STUDY TO IDENTIFY NOVEL MELANOMA RISK GENES. 7. 3-YEAR GRANT FROM THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR), TOTALING $8,180,465 (A TOTAL OF NEARLY $18 MILLION WHEN INCLUDING FUNDS IN PARTNERSHIP WITH THE UNIVERSITY OF PENNSYLVANIA) TO DR. DANIEL VON HOFF TO DEVELOP REVOLUTIONARY TREATMENTS FOR PANCREATIC CANCER. 8. 2-YEAR GRANT FOR THE NATIONAL INSTITUTES OF HEALTH (NIH), TOTALING $7,551,533, TO DR. NATHALIE MEURICE AND DR. SPYRO MOUSSES TO ESTABLISH, IN CONJUNCTION WITH THE UNIVERSITY OF ARIZONA, THE SOUTHWEST COMPREHENSIVE CENTER FOR DRUG DISCOVERY AND DEVELOPMENT TO HELP TRANSFORM LABORATORY DISCOVERIES INTO NEW DRUG COMPOUNDS. 9. 2-YEAR NIH GRANT, TOTALING $4,259,456, TO DR. JEFFREY TRENT TO START, IN CONJUNCTION WITH THE VAN ANDEL RESEARCH INSTITUTE, THE CANINE HEREDITARY CANCER CONSORTIUM, WHICH WILL USE STUDIES OF DOGS TO HELP DISCOVER NEW TREATMENTS FOR RARE CANCERS IN BOTH HUMANS AND DOGS. 10. 2-YEAR NIH GRANT, TOTALING $3,576,502, TO DR. DAVID DUGGAN FOR A GENOME-WIDE ASSOCIATION STUDY TO HELP IDENTIFY THE GENETIC ORIGINS OF ARTHRITIS OF THE KNEE. 11. 2-YEAR GRANT FROM THE U.S. DEPARTMENT OF DEFENSE AND THE TELEMEDICINE & ADVANCED TECHNOLOGY RESEARCH CENTER, TOTALING $1,697,999, TO DR. PAUL KEIM TO CREATE TESTS THAT WOULD RAPIDLY CHARACTERIZE AND IDENTIFY THE NATURAL OR MAN-MADE SOURCES OF DISEASE OUTBREAKS. 12. 2-YEAR NIH GRANT, TOTALING $1,436,000, TO DR. DAVID CRAIG FOR DATA PROCESSING AND VISUALIZATION IN CONJUNCTION WITH THE INTERNATIONAL 1000 GENOMES PROJECT, WHICH WOULD CATALOGUE COMMON HUMAN GENETIC VARIABILITY. 13. TWO, 2-YEAR NIH GRANTS, TOTALING $1,093,274 AND $225, 044, TO DR. DAVID DUGGAN FOR ADVANCING THE STUDY OF THE EPIDEMIOLOGY OF PUTATIVE GENUINE GENETIC VARIANTS. ENTERPRISE EFFORTS AND COLLABORATION TGEN'S OFFICES OF BUSINESS DEVELOPMENT AND TECHNOLOGY TRANSFER WORK TO DEVELOP AN APPROPRIATE ADMINISTRATIVE STRUCTURE TO HANDLE COMMERCIALIZATION OF ITS INTELLECTUAL PROPERTY, AS WELL AS TO DEVELOP EFFECTIVE WAYS TO PARTNER WITH THE COMMERCIAL SECTOR. THE TECHNOLOGY TRANSFER OFFICE (TTO) FACILITATES AND ACCELERATES THE COMMERCIALIZATION OF TGEN'S SCIENTIFIC DISCOVERIES FOR THE BENEFIT OF HUMAN HEALTH BY: - IDENTIFYING, PATENTING AND LICENSING NEW TECHNOLOGY; - FACILITATING ACCESS AND EXCHANGE OF RESEARCH MATERIALS, TECHNOLOGIES, AND DATA VIA MATERIAL TRANSFER AGREEMENTS (MTAS) OR CONFIDENTIAL DISCLOSURE AGREEMENTS (CDAS); - NEGOTIATING COLLABORATIVE RESEARCH AGREEMENTS; AND - ASSISTING IN THE FORMATION OF START-UP COMPANIES WHEN APPROPRIATE. INVENTION DISCLOSURES TGEN SCIENTISTS WORK WITH THE OFFICE OF TECHNOLOGY TRANSFER (OTT) TO FILE INVENTION DISCLOSURES AS THE FIRST STEP TOWARD A POSSIBLE PATENT APPLICATION OR OTHER APPROPRIATE FORM OF INTELLECTUAL PROPERTY PROTECTION. TGEN FILED 26 INVENTION DISCLOSURES IN FY10 BASED ON DISCOVERIES STEMMING FROM TGEN-LED RESEARCH AND FILED 21 PROVISIONAL PATENT APPLICATIONS. COMMERCIALIZATION / SPIN OFFS IN TERMS OF COMMERCIALIZATION AND COMPANY FORMATION, TGEN SIGNED 3 LICENSE AGREEMENTS IN FY10.
CONTRACTS AND COLLABORATIONSTGEN SIGNED A TOTAL OF 386 CONTRACTS IN FY10, BROKEN DOWN AS FOLLOWS: 1. TGEN SIGNED 87 CONFIDENTIAL DISCLOSURE AGREEMENTS (CDA) IN FY10. 2. TGEN SIGNED 102 MATERIAL TRANSFER AGREEMENTS (MTA) IN FY10. 3. TGEN SIGNED 85 RESEARCH COLLABORATIONS (ANY WITH LOCAL AND STATE AFFILIATIONS) IN FY10, INCLUDING AGREEMENTS THAT FURTHER RESEARCH INTO A HOST OF DISEASES, INCLUDING BRAIN CANCER, MELANOMA, ALZHEIMER'S AND AUTISM. 4. ADDITIONALLY, TGEN SIGNED 18 CONSULTING AGREEMENTS, 69 PROFESSIONAL SERVICES AGREEMENTS, 9 COMMERCIALIZATION LICENSES, AND 16 AGREEMENTS COVERING MISCELLANEOUS ACTIVITIES. JOB CREATION 36 NEW FULL-TIME EQUIVALENT POSITIONS WERE CREATED IN FY10 WITH SALARIES AND BENEFITS TOTALING APPROXIMATELY $2,550,475. SALARIES FOR TEMPORARY POSITIONS (THOSE POSITIONS CREATED FOR A FINITE PERIOD OF TIME) TOTALED $160,000 AND STUDENT SALARIES WERE JUST OVER $390,000, BRINGING THE OVERALL TOTAL TO $3,100.475. TGEN STAFF NOW TOTAL 284, OF WHICH 83 PERCENT HOLD A COLLEGE DEGREE (48 PERCENT HOLD AN ADVANCED DEGREE). FY10 POSITIONS FILLED INCLUDE: ADMINISTRATIVE ASSISTANT ASSOCIATE INVESTIGATOR DEVELOPMENT ASSOCIATE BIOINFORMATICIAN BIOINFORMATICIAN II CLINICAL INFORMATICS PROGRAMMER CLINICAL TRANSLATIONAL RESEARCH DIVISION, DEPUTY DIRECTOR DESKTOP SUPPORT SPECIALIST GRANT PROGRAM MANAGER OPERATIONS MANAGER POST-DOCTORAL FELLOW RESEARCH ASSOCIATE RESEARCH ASSOCIATE II SOFTWARE ENGINEER SOFTWARE QA ENGINEER SENIOR INVESTIGATOR SENIOR STAFF SCIENTIST STAFF SCIENTIST WE HAVE STRESSED IN THE PAST THAT INTERNSHIPS SERVE AS A PIPELINE TO TGEN IN TERMS OF FUTURE RECRUITMENT AND SUPPORT THE STATEWIDE INITIATIVE TOWARDS EDUCATION AND DEVELOPMENT FOR THE STUDENTS IN THE LIFE SCIENCES. ADDITIONALLY, TGEN IS A PROVING GROUND WHERE TALENTED UNDERGRADUATES GAIN VALUABLE EXPERIENCE PRIOR TO RETURNING TO EARN ADVANCED DEGREES AT ONE OF THE STATE'S THREE UNIVERSITIES. TGEN HIRED FOUR SUCH CANDIDATES IN FY10, WHILE 14 EMPLOYEES RETURNED TO UNIVERSITY TO FURTHER THEIR BIOMEDICAL EDUCATION. EDUCATION AND PUBLIC OUTREACH INTERNSHIPS 2010 SAW 44 BIOSCIENCE STUDENTS COMPLETING THE 2010 HELIOS SCHOLARS PROGRAM AT TGEN, AND 23 NON-HELIOS STUDENTS CONDUCTING INTERNSHIPS - SCIENTIFIC AND ADMINISTRATIVE - IN A NUMBER OF TGEN LABS AND DEPARTMENTS. SIXTEEN FEMALES AND 28 MALES COMPRISED THE HELIOS SCHOLARS, BROKEN DOWN AS FOLLOWS: 32 PERCENT HIGH SCHOOL, 57 PERCENT UNDERGRADUATE, AND 11 PERCENT GRADUATE/MEDICAL SCHOOL. SEVENTEEN FEMALES AND SIX MALES COMPRISED THE 23 NON HELIOS STUDENTS CONDUCTING INTERNSHIPS AT TGEN IN FY10, BROKEN DOWN AS FOLLOWS: 9 PERCENT HIGH SCHOOL, 70 PERCENT UNDERGRADUATE, AND 21 PERCENT GRADUATE/MEDICAL SCHOOL. NEW IN FY10 (FALL '09), TGEN AND THE PHOENIX BIOSCIENCE HIGH SCHOOL LAUNCHED A PILOT INTERNSHIP PROGRAM FOR THEIR SENIOR STUDENTS. THE STUDENTS RECEIVE CREDIT IN EXCHANGE FOR THE COMPLETION OF A MINIMUM NUMBER OF HOURS (120) IN A RESEARCH LAB ENVIRONMENT. TEACHER TRAINING PROGRAM IN FY10, TGEN COMPLETED ITS SECOND YEAR OF A 5-YEAR TRAINING AWARD IN COLLABORATION WITH NORTHERN ARIZONA UNIVERSITY TO CONDUCT A SUMMER GENOMICS WORKSHOP FOR TEACHERS AND GRADUATE STUDENTS AS PART OF AN NSF GRANT CALLED BIOTECHNOLOGY INTEGRATION OPPORTUNITIES FOR TEACHER EDUCATION AND CONTENT (BIOTEC). THIS GRANT PARTNERS THE COLLEGE OF ENGINEERING AND NATURAL SCIENCES, THE COLLEGE OF EDUCATION AT NORTHERN ARIZONA UNIVERSITY, AND TGEN IN ORDER TO ENHANCE INQUIRY-BASED SCIENCE TEACHING IN GRADES 5, 7, AND 9 WHILE EXPANDING THE INTERDISCIPLINARY PREPARATION OF GRADUATE STUDENTS IN BIOTECHNOLOGY. EDUCATIONAL AND PUBLIC TOURS IN FY10, TGEN HOSTED 46 PUBLIC TOURS FOR A DIVERSE RANGE OF COMMUNITY MEMBERS AND ORGANIZATIONS (TOTALING NEARLY 1,000 IN NUMBER), AS WELL AS SENT REPRESENTATIVES INTO THE COMMUNITY TO PRESENT AT FUNCTIONS, CAREER AND EDUCATIONAL FAIRS. STIMULATING GROWTH OF ARIZONA'S LIFE SCIENCE INDUSTRIES AN IMPORTANT FACTOR IN CONTINUING TGEN'S SUCCESS IS COMMUNICATION WITH VARIOUS STAKEHOLDERS AND THE BROADER ARIZONA COMMUNITY. TOWARD THAT GOAL, TGEN SR. LEADERSHIP PARTICIPATES IN A MYRIAD OF COMMUNITY-RELATED ACTIVITIES THROUGH PRESENTATIONS AT REGIONAL MEETINGS AND AS A MEMBER OR PARTICIPANT OF VARIOUS COMMITTEES AND GROUPS, INCLUDING THE ARIZONA ALZHEIMER'S CONSORTIUM BOARD, ARIZONA BIOSCIENCE ROADMAP STEERING COMMITTEE AND ARIZONA BIOSCIENCE ROADMAP EDUCATION & WORKFORCE DEVELOPMENT COMMITTEE, ARIZONA SKILL STANDARDS COMMISSION, ARIZONA TECHNOLOGY COUNCIL, GREATER PHOENIX LEADERSHIP, NSF STEP GRANT ADVISORY BOARD- FOR ESTRELLA MOUNTAIN CC AND MORE.
MEDIATGEN REMAINS ACTIVE IN PURSUING POSITIVE EARNED MEDIA EXPOSURE FOR THE INSTITUTE'S RESEARCH AND PHILANTHROPIC ACTIVITIES. MEDIA EXPOSURE RAISES AWARENESS AND BRINGS ADDED CREDIBILITY TO THE INSTITUTE AND THE STATE. IN TOTAL, TGEN RECEIVED GREATER THAN 1300 MEDIA MENTIONS IN FY10 IN VARIOUS TRADE AND PUBLIC MEDIA: LOCALLY, NATIONALLY AND INTERNATIONALLY. WHILE CITING TGEN SPECIFICALLY, THESE ARTICLES AND NEWS BRIEFS HELP BUILD A GREATER PRESENCE FOR THE CONTINUOUSLY EXPANDING BIOMEDICAL SCIENCE INITIATIVES OCCURRING IN ARIZONA. MEDIA OUTLETS INCLUDE: FOX10 NEWSMAKER SUNDAY BUSINESS WIRE STATES NEWS SERVICE THE ARIZONA REPUBLIC PHOENIX BUSINESS JOURNAL ARIZONA BUSINESS GAZETTE ARIZONA DAILY STAR JEWISH NEWS OF GREATER PHOENIX GRAND RAPIDS PRESS THE STAR-LEDGER (NEWARK, N.J.) PLAIN DEALER (CLEVELAND) ASIAN NEWS INTERNATIONAL (ANI) BIOTECH WEEK PR NEWSWIRE MARKETWIRE THE HILL LIFE SCIENCE WEEKLY HEALTH & MEDICINE WEEK GENOMEWEB ON-LINE TGEN'S ON-LINE PRESENCE CONTINUES TO INCREASE ON AN ANNUAL BASIS. WITH TWO ACTIVE SITES (TGEN AND THE TGEN FOUNDATION) MORE THAN 1.2 MILLION PAGE VIEWS WERE RECORDED IN FY10. THE WEB SERVES AS A PORTAL TO ALLOW ARIZONANS - AND OTHERS WORLDWIDE- TO LEARN ABOUT THE RESEARCH AND DISCOVERIES COMING OUT OF TGEN LABS. ADDITIONALLY, THE TGEN FOUNDATION WEB PAGES ALLOW SUPPORTERS TO CREATE MEMORIALS AND FUNDRAISING PAGES IN SUPPORT OF TGEN'S EFFORTS TO DEVELOP IMPROVED DIAGNOSTIC TOOLS AND NEW THERAPEUTICS THAT TARGET A HOST OF DISEASES. TGEN'S RECENTLY LAUNCHED SOCIAL MEDIA (FACEBOOK, TWITTER) PROVIDES A FURTHER OPPORTUNITY TO COMMUNICATE WITH NUMEROUS CONSTITUENCIES THROUGH EVER-INCREASING MEDIUMS.
FORM 990, PART VI, LINE 6DESCRIPTION OF SIGNIFICANT CHANGES TO BYLAWSFORM 990, PART VI, LINE 6 CLASSES OF MEMBERS AND THE NATURE OF THEIR RIGHTS LINE 6 - THE SOLE CORPORATE MEMBER OF THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE FOUNDATION (TGEN FOUNDATION) IS THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (TGEN).
FORM 990, PART VI, LINES 7A & 7BDECISIONS REQUIRING APPROVALLINE 7A - TGEN, AS THE SOLE CORPORATE MEMBER OF TGEN FOUNDATION, HAS THE RIGHT TO ELECT THE BOARD OF DIRECTORS OF TGEN FOUNDATION. LINE 7B - THE SOLE CORPORATE MEMBER'S VOTE SHALL BE REQUIRED ON: A) THE ELECTION AND REMOVAL OF ELECTED DIRECTORS AS SET FORTH IN THE BYLAWS; B) THE ADOPTION OF ANY PLAN OF MERGER OR CONSOLIDATION; C) THE SALE OF ALL OR SUBSTANTIALLY ALL THE FOUNDATION'S ASSETS IN A SINGLE TRANSACTION OR SERIES OF RELATED TRANSACTIONS; D) THE AMENDMENT OF THE FOUNDATION'S ARTICLES OF INCORPORATION OR BYLAWS; E) THE INSTITUTION, OR CONSENT TO INSTITUTION, OF PROCEEDINGS TO ADJUDICATE THE FOUNDATION BANKRUPT OR INSOLVENT, OR THE FILING OF A PETITION SEEKING OR CONSENTING TO REORGANIZATION OR RELIEF UNDER ANY LAW RELATING TO BANKRUPTCY, INSOLVENCY, OR OTHER RELIEF FOR DEBTORS, OR THE CONSENT TO THE APPOINTMENT OF A RECEIVER, LIQUIDATOR, ASSIGNEE, TRUSTEE, SEQUESTRATOR (OR SIMILAR OFFICIAL) OF THE FOUNDATION OR OF ALL OR ANY SUBSTANTIAL PART OF ITS PROPERTY, OR THE MAKING OF ANY ASSIGNMENT FOR THE BENEFIT OF CREDITORS, OR THE ADMISSION IN WRITING OF THE FOUNDATION'S INABILITY TO PAY ITS DEBTS GENERALLY AS THEY BECOME DUE, OR ANY STEPS IN FURTHERANCE OF SUCH ACTION; AND F) THOSE MATTERS UPON WHICH THE MEMBER IS GRANTED VOTING RIGHTS IN THE ARTICLES OF INCORPORATION, BYLAWS, OR THE ARIZONA NONPROFIT CORPORATION ACT. THE SOLE CORPORATE MEMBER HAS THE FOLLOWING RESERVE POWERS: A) APPOINT AND REMOVE THE PRESIDENT; B) APPROVE THE ESTABLISHMENT OF NEW CORPORATE PARTNERSHIP ENTITIES CREATED OR JOINED BY THE FOUNDATION; C) APPROVE THE FOUNDATION'S EXECUTION OF MATERIAL CONTRACTS; AND D) APPROVE THE FOUNDATION'S INCURRENCE OF MATERIAL DEBTS.
FORM 990, PART VI, LINE 11PROCESS USED BY MANAGEMENT AND/OR GOVERNING BODY TO REVIEW FORM 990THE FORM 990 IS PREPARED BY AN OUTSIDE ACCOUNTING FIRM BASED ON INFORMATION PROVIDED BY THE FINANCE DEPARTMENT. THE 990 IS THEN REVIEWED BY MANAGEMENT IN THE FINANCE DEPARTMENT AND POSTED ON THE BOARD WEBSITE.
FORM 990, PART VI, LINE 12CPROCESS USED TO MONITOR TRANSACTIONS FOR CONFLICTS OF INTERESTTGEN Foundation issues a conflict of interest questionnaire on an annual basis to all Foundation Director level positions and above in addition to any key employees designated by the Foundation President and/or Chief Operating Officer. The questionnaires are reviewed by the Chief Financial Officer and those employees with conflicts are sent for further review to the Foundation President and/or Chief Operating Officer to ensure a plan is set forth. Updates to the list are handled on an as needed basis based on contract reviews and employee information.
FORM 990, PART VI, LINES 15A AND 15BPROCESS USED TO DETERMINE COMPENSATIONTGen Foundation does not have any direct employees. Compensation is determined by The Translational Genomics Research Institute (Tgen) using the following process: TGen's Governance and Executive Compensation Committee will act in an "advice and consent" capacity reviewing the recommendations for the President and Scientific Director regarding the compensation of disqualified persons and forwarding final recommendations to the full Board for approval. Disqualified persons (except for the President and Scientific Director) will not be present for, or participate in, Committee deliberations concerning their compensation (other than to answer questions). The President and Scientific Director will participate in the deliberations concerning the compensation of direct reports. During the decision-making process, the Committee will adhere to the Executive Compensation philosophy. The Committee is authorized (and provided with sufficient funding) to annually engage outside independent compensation and legal advisors when deemed necessary and advisable. The Committee will comply with the "Rebuttable Presumption of Reasonableness" under Section 4958 of the Internal Revenue Code whenever possible. The Committee will review and understand the Internal Revenue Code provisions dealing with "excess benefit transactions concerning Disqualified Persons' compensation". When developing a compensation philosophy, TGen kept in mind the following factors: The TGen mission and strategy The TGen culture Trends in compensation in the external environment Trends in recruitment of new employees Trends in organizational employee turnover TGen's life cycle stage
FORM 990, PART VI, LINE 19AVAILABILITY OF GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, ANDFINANCIAL STATEMENTS TO THE GENERAL PUBLIC TGEN FOUNDATION PROVIDES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY AND FINANCIAL STATEMENTS TO THE GENERAL PUBLIC UPON REQUEST.
FORM 990, PART VIIHOURS DEVOTED TO RELATED ORGANIZATIONSTHE ORGANIZATION DOES NOT DIRECTLY HAVE ANY EMPLOYEES. THE FOLLOWING INDIVIDUALS REPORTED IN PART VII ARE PAID BY THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (TGEN), A RELATED TAX-EXEMPT ORGANIZATION, FOR SERVICES PROVIDED TO TGEN FOUNDATION: MICHAEL BASSOFF DENISE MCCLINTIC THESE INDIVIDUALS DEVOTE 40 HOURS PER WEEK TO TGEN FOUNDATION AND NO HOURS PER WEEK TO TGEN. THE FOLLOWING INDIVIDUALS REPORTED IN PART VII ARE PAID BY THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (TGEN), A RELATED TAX-EXEMPT ORGANIZATION, FOR SERVICES PROVIDED TO TGEN: JEFFREY TRENT TERESA BURLESON THEY DEVOTE 40 HOURS PER WEEK TO TGEN AND 1 HOUR PER WEEK TO TGEN FOUNDATION.

Schedule R IRS990ScheduleR

Form990 Schedule R Part II Form990ScheduleRPartII (2 entries)

Address Line1AddressUS/AddressLine1CityAddressUS/CityStateAddressUS/StateZIP CodeAddressUS/ZIPCodeEINEINPrimary ActivitiesPrimaryActivitiesLegal Domicile StateLegalDomicileStateExempt Code SectionExemptCodeSectionPublic Charity StatusPublicCharityStatusBusiness Name Line1DirectControllingEntityName/BusinessNameLine1
THE TRANSLATIONAL GENOMICS RESEARCH INST
445 NORTH 5TH STREETPHOENIXAZ85004753065445RESEARCHAZ501(C)(3)7VARI
VAN ANDEL RESEARCH INSTITUTE
333 BOSTWICK AVE STE 850GRAND RAPIDSMI49503522000823MEDICAL RSCHMI501(C)(3)4NA
FieldValueIRS element (for citing)
Receipt Of Int Ann Rents RoyaltiesfalseReceiptOfIntAnnRentsRoyalties
Gift Grant Or Cap Contr To Other OrgtrueGiftGrantOrCapContrToOtherOrg
Gift Grant Or Cap Contr Fr Other OrgfalseGiftGrantOrCapContrFrOtherOrg
Loans Or Guarantees To Other OrgfalseLoansOrGuaranteesToOtherOrg
Loans Or Guarantees From Other OrgfalseLoansOrGuaranteesFromOtherOrg
Sale Of Assets To Other OrgfalseSaleOfAssetsToOtherOrg
Purchase Of Assets From Other OrgfalsePurchaseOfAssetsFromOtherOrg
Exchange Of AssetsfalseExchangeOfAssets
Rental Of Facilities To Other OrgsfalseRentalOfFacilitiesToOtherOrgs
Rental Of Facilities Fr Other OrgsfalseRentalOfFacilitiesFrOtherOrgs
Perform Of Services For Other OrgstruePerformOfServicesForOtherOrgs
Perform Of Services By Other OrgsfalsePerformOfServicesByOtherOrgs
Sharing Of FacilitiesfalseSharingOfFacilities
Sharing Of Paid EmployeesfalseSharingOfPaidEmployees
Reimbursement Paid To Other OrgfalseReimbursementPaidToOtherOrg
Reimbursement Paid By Other OrgtrueReimbursementPaidByOtherOrg
Other Transfer To Other OrgfalseOtherTransferToOtherOrg
Other Transfer From Other OrgfalseOtherTransferFromOtherOrg

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.